Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target

Amylyx Pharmaceuticals is supported by a fundamentally improved risk/reward profile after LUCIDITY showed avexitide reduced composite Level 2/3 hypoglycemic events by 55% versus placebo with p=0.000003, while also meeting all secondary endpoints and showing a clean safety profile. The data strengthen the case for first-ever treatment leadership in post-bariatric hypoglycemia, a rare endocrine market with no approved comparator, Breakthrough Therapy and Orphan Drug designations, and a large addressable US population of roughly 160,000 moderate-to-severe patients. With an NDA planned by year-end, a 2027 launch guided, and modeled avexitide sales of $3.5B in 2035E, the company appears well positioned for broad reimbursement, durable uptake, and a materially better path to profitability.

Amylyx Pharmaceuticals is viewed negatively because its valuation hinges on a narrow set of clinical and regulatory catalysts, and any Phase 3 adults with PBH readout that misses efficacy or safety expectations could sharply weaken the investment case. The company also faces meaningful execution risk from unforeseen delays in R&D, regulatory, or commercial development, which is especially problematic for a clinical-stage company without established product revenue to buffer setbacks. In addition, competition in the PBH space and the possibility that the PBH market opportunity falls below expectations create further downside, since the pipeline across avexitide, AMX0035, AMX0114, and AMX0318 remains highly dependent on future trial success.